

ASX ANNOUNCEMENT

4 December 2025

Saluda Investor Webinar

Sydney, Australia -- Saluda Medical, Inc. (ASX:SLD, “**Saluda**” or the “Company”), a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform, is pleased to advise it will host an investor webinar on Friday, 5 December 2025 at 10:00am AEDT.

Saluda Chief Executive Officer, Barry Regan, and Chief Financial Officer, James Erickson, will join the session to introduce the Company and discuss its operations and outlook. The webinar will precede Saluda trading on the ASX (under the ticker “SLD”), anticipated to commence at 11.00am AEDT the same day, Friday, 5 December 2025.

Register for the webinar via the link below:

https://us02web.zoom.us/webinar/register/WN_vzsQ3u33RKmhEqixySNzFA

Participants will receive a confirmation email containing details to join the webinar.

Investors may also submit questions prior to the webinar to sam@nwrcommunications.com.au or during the webinar via the Q&A function within Zoom.

Authorised for release by the Chief Financial Officer, James Erickson.

For more information, please contact:

Investors

James Erickson
Chief Financial Officer
investors@saludamedical.com

Sam Wells
NWR Communications
+61 (0) 427 630 152
sam@nwrcommunications.com.au

Media

Matt Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Saluda Medical

Saluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. The Company’s closed-loop, dose-control platform senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. The Company’s first product, the Evoke® System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy

SALUDA MEDICAL, INC.
ARBN 691 140 360
9401 James Ave S, Suite 132
Bloomington MN 55431, United States

that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. 12-month results from the EVOKE study, the first and only prospective, multi-center, parallel-arm, doubleblind, randomized controlled pivotal study with a voluntary crossover arm in SCS, that demonstrated clinically superior pain relief to open-loop therapy, were published in The Lancet Neurology, 24-month results were published in JAMA Neurology, and 36-month data, that demonstrated sustained pain relief, were published in Regional Anesthesia and Pain Medicine. To learn more, including risks and important safety information, visit www.saludamedical.com/us/safety/.

SALUDA MEDICAL, INC.

ARBN 691 140 360

9401 James Ave S, Suite 132

Bloomington MN 55431, United States